Business
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter Harwin named Chairman of the Board of Directors -- BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that its Board of Directors has appointed Jennife
About this update from Damora Therapeutics, Inc.
[{"type":"image","alt":"Damora Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Damora Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/39e722f9d4ca06880ac12b134774dc44"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y_f1Ey89t1gW3ao7vlUd2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNA--/https://media.zenfs.com/en/globenewswire.com/39e722f9d4ca06880ac12b134774dc44","width":300,"height":74}},"lazy":false},{"type":"text","content":"-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance --","length":98,"tagName":"p"},{"type":"text","content":"-- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors --","length":92,"tagName":"p"},{"type":"text","content":"-- Peter Harwin named Chairman of the Board of Directors --","length":59,"tagName":"p"},{"type":"text","content":"BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that its Board of Directors has appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. Ms. Jarrett will also serve on the company’s Board of Directors.","length":390,"tagName":"p"},{"type":"text","content":"“We are excited to welcome Jen to Damora as we accelerate our efforts to bring innovative medicines to patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasm (MPNs),” said Peter Harwin, Chairman of the Board of Directors of Damora Therapeutics. “With a track record of success in oncology drug development and building and leading high-growth companies, Jen brings a unique set of strategic and operational experience that will be invaluable as we unlock Damora’s potential.”","length":499,"tagName":"p"},{"type":"text","content":"“I am thrilled to join Damora, and I look forward to working alongside the company’s talented and purpose-driven employees to realize our mission of redefining care for people with blood disorders,” said Jennifer Jarrett, President and Chief Executive Officer of Damora Therapeutics. “With a portfolio of potential best-in-class therapies, a strong balance sheet, and experienced board and executive leadership, Damora is e...